Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
Mersana Therapeutics reports 2023 executive compensation
By ExecPay News
Published: April 26, 2024
Mersana Therapeutics reported fiscal year 2023 executive compensation information on April 26, 2024.
In 2023, seven executives at Mersana Therapeutics received on average a compensation package of $2.2M, a 44% increase compared to previous year.
Average pay of disclosed executives at Mersana Therapeutics
Anna Protopapas, Chief Executive Officer, received $4.5M in total, which increased by 56% compared to 2022. 68% of Protopapas' compensation, or $3M, was in option awards. Protopapas also received $448K in salary, $758K in stock awards, as well as $225K in other compensation.
Martin Huber, Chief Executive Officer, received a compensation package of $2.6M. 44% of the compensation package, or $1.1M, was in option awards.
Arvin Yang, Chief Medical Officer, earned $1.9M in 2023, a 24% increase compared to previous year.
Brian DeSchuytner, Chief Financial Officer, received $1.7M in 2023, which increases by 34% compared to 2022.
Timothy B. Lowinger, Senior Vice President, Chief Science and Technology Officer, earned $1.7M in 2023, a 43% increase compared to previous year.
Alejandra Carvajal, Chief Legal Officer, received $1.6M in 2023, which increases by 84% compared to 2022.
Mohan Bala, Senior Vice President, Chief Development Officer, earned $1.6M in 2023.
Related executives
Martin Huber
Mersana Therapeutics
Chief Executive Officer
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
Brian DeSchuytner
Mersana Therapeutics
Chief Financial Officer
Mohan Bala
Mersana Therapeutics
Senior Vice President, Chief Development Officer
Alejandra Carvajal
Mersana Therapeutics
Chief Legal Officer
Timothy Lowinger
Mersana Therapeutics
Senior Vice President, Chief Science and Technology Officer
Arvin Yang
Mersana Therapeutics
Chief Medical Officer
You may also like
Source: SEC filing on April 26, 2024.